Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1644
This examiner grants 61% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18258925 | Fc-Receptor CAR Constructs and Cells | Non-Final OA | ImmunityBio, Inc. |
| 18270996 | ADJUVANTS TO STIMULATE BROAD AND PERSISTENT INNATE IMMUNITY AGAINST DIVERSE ANTIGENS | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18247245 | COMBINATION THERAPY WITH ANTI-PVRIG ANTIBODIES FORMULATIONS, ANTI-TIGIT ANTIBODIES, AND ANTI-PD-1 ANTIBODIES | Non-Final OA | Bristol-Myers Squibb Company |
| 17418343 | ANTI-EPHRIN-B2 BLOCKING ANTIBODIES FOR THE TREATMENT OF FIBROTIC DISEASES | Final Rejection | The General Hospital Corporation |
| 19030139 | D-DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF | Non-Final OA | Arcellx, Inc. |
| 17443562 | COMPOSITIONS AND METHODS FOR REDUCING ANTIGEN-SPECIFIC IMMUNOGENICITY | Non-Final OA | The Research Foundation for The State University of New York |
| 18275986 | SARBECOVIRUS BINDERS | Non-Final OA | VRIJE UNIVERSITEIT BRUSSEL |
| 18302636 | COMBINATIONAL IMMUNOTHERAPIES USING CAR-M, CAR-NK, CAR-EOS, AND CAR-N CELLS | Non-Final OA | Wisconsin Alumni Research Foundation |
| 18297069 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | Non-Final OA | Immatics Biotechnologies GmbH |
| 18039420 | BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA | Non-Final OA | NANJING LEGEND BIOTECH CO., LTD. |
| 18280068 | ANTI-VSIG4 ANTIBODY OR ANTIGEN BINDING FRAGMENT AND USES THEREOF | Non-Final OA | Y-BIOLOGICS INC. |
| 18451025 | NON-PLATELET DEPLETING AND NON-RED BLOOD CELL DEPLETING CD47 ANTIBODIES AND METHODS OF USE THEREOF | Non-Final OA | Inhibrx Biosciences, Inc. |
| 17605695 | BI-FUNCTIONAL HUMANIZED ANTI-C5 ANTIBODIES AND FACTOR H FUSION PROTEINS AND USES THEREOF | Final Rejection | Kira Pharmaceuticals (US) LLC |
| 18258200 | EPCAM BINDING MOLECULES AND USES THEREOF | Non-Final OA | BioArdis, LLC |
| 18162344 | BISPECIFIC ANTIBODY THERAPIES | Non-Final OA | CytoAgents, Inc. |
| 17997576 | IMMUNE CELL TREATED BY MEANS OF MAGNETIC FIELD AND USE THEREOF | Final Rejection | CENTER FOR EXCELLENCE IN MOLECULAR CELL SCIENCE, CHINESE ACADEMY OF SCINCES |
| 18172433 | CONSTRAINED CONDITIONALLY ACTIVATED BINDING PROTEINS | Non-Final OA | TAKEDA PHARMACEUTICAL COMPAMY LIMITED |
| 18095484 | Engineered T Cells | Non-Final OA | Expression Therapeutics, LLC |
| 17760394 | Antibodies Conjugated with Fatty Acid Molecules and Uses Thereof | Final Rejection | Phanes Therapeutics, Inc. |
| 17420000 | MULTI-SPECIFIC PROTEIN MOLECULES AND USES THEREOF | Non-Final OA | Trio Pharmaceuticals, Inc. |
| 17252864 | ANTIBODIES ANTI TUMOR ASSOCIATED ANTIGENS AND METHOD FOR OBTAINING THEM | Non-Final OA | IEO - ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. |
| 16759937 | ANTIBODIES TO alpha-SYNUCLEIN AND USES THEREOF | Final Rejection | ABL Bio Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy